Trials / Withdrawn
WithdrawnNCT00210340
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin's lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intrathecal rituximab |
Timeline
- First posted
- 2005-09-21
- Last updated
- 2015-03-30
Source: ClinicalTrials.gov record NCT00210340. Inclusion in this directory is not an endorsement.